Compare SB & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SB | IRWD |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | Monaco | United States |
| Employees | 1107 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 651.7M | 658.5M |
| IPO Year | N/A | 2009 |
| Metric | SB | IRWD |
|---|---|---|
| Price | $6.82 | $3.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $7.67 |
| AVG Volume (30 Days) | 1.0M | ★ 2.7M |
| Earning Date | 05-18-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $3.47 | $57.95 |
| Revenue Next Year | $3.61 | $4.39 |
| P/E Ratio | $16.77 | ★ $16.10 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $3.61 | $0.72 |
| 52 Week High | $7.38 | $5.78 |
| Indicator | SB | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 45.35 |
| Support Level | $6.29 | $3.80 |
| Resistance Level | $7.30 | $3.95 |
| Average True Range (ATR) | 0.22 | 0.24 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 57.02 | 7.51 |
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain, and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services. The company generates almost all of its revenue from Time Charters.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.